Navigation Links
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Date:8/28/2008

statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

ThromboGenics

Patrik De Haes, CEO

Tel : +32-16-75-13-10

patrik.dehaes@thrombogenics.com

Desire Collen, Chairman

Tel : +32-16-75-13-10

desire.collen@thrombogenics.com

Citigate Dewe Rogerson

Amber Bielecka/Sylvie Berrebi/David Dible

Tel : +44(0)207-638-95-71

amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
2. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
3. ThromboGenics N.V. - Business Update
4. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
5. ThromboGenics Announces 2007 Full Year Results
6. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
11. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... TX, USA (PRWEB) , ... July 30, 2015 ... ... and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , ... positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... 2008 Martek,Biosciences Corporation announced today that the ... has entered a Final Judgment and Order,of Dismissal ... on behalf of certain purchasers of Martek common ... securities laws and arose out of,allegations, among other ...
... April 7, 2008 Microbia, Inc. today,announced that ... Inc.,The ironwood is a long-lived tree that thrives ... as long as 1,500 years. Known as a,"nurse ... temperatures,higher water availability, and more organic matter for ...
... advance collaborative research worldwide, HUNTSVILLE, Ala., ... today that leading research institutions, the Institute ... University of,Queensland, and the Biotech Research and ... Copenhagen have recently purchased access to Open,Biosystems ...
Cached Biology Technology:Martek Announces Final Judgment and Order of Dismissal in Class Action 2Microbia Announces Name Change to Ironwood Pharmaceuticals 2Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland 2Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland 3
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... life sciences journal F1000Research is that ... the article. Openly sharing data is an important step in ... published research, as well as enabling data reuse. ... the data in the journal,s articles to be assessed and ...
... balanced interplay of four molecules that trigger and govern ... an important basic science discovery, it helps explain why ... genes cannot fight infection effectively, and develop rare and ... of a number of different types of cells that ...
... poison-dart frog, a red male isn,t much brighter than a green ... the green and red variants of the same species of frog ... Ecology and Sociobiology , led by Beatriz Willink of the Universidad ... The bright colors of poison-dart frogs serve not only ...
Cached Biology News:F1000Research launch data plotting tool 2Molecular interplay explains many immunodeficiencies 2Green poison-dart frog varies mating call to suit situation 2
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Biology Products: